<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="102361">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01711060</url>
  </required_header>
  <id_info>
    <org_study_id>CICATAC</org_study_id>
    <nct_id>NCT01711060</nct_id>
  </id_info>
  <brief_title>A Comparison of Balloon Catheter Versus Ocytocin for Cervical Ripening on Scarred Uterus With Unfavorable Cervix</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      Increasing cesarean rate in France is worrying. Different  methods are described for
      ripening labor : the use of prostaglandins is described but maybe dangerous for patients
      with scarred uterus and is not recommended.

      Intracervical balloon is an efficient alternative methods which as already been tested for
      unfavorable cervix ripening on nulliparous women.

      But it was rarely tested on women with scared uterus and unfavorable cervix (bishop score
      &lt;4).

      The investigators propose a prospective randomised trial comparing cervix ripening with
      intracervical balloon inflated by 50 ml sterile water during 12 hours versus ocytocin
      (reference method).

      The investigators expect  to demonstrate what it's a safe method to increase vaginal
      delivery for women with previous cesarean section who need an induction of labour.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>N/A</study_design>
  <primary_outcome>
    <measure>Rate of childbirth by low way</measure>
    <description>The childbirth by low way being considered as a success of the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of incidence of materno-fœtales morbidity</measure>
    <description>number</description>
  </secondary_outcome>
  <condition>Scarred Uterus</condition>
  <arm_group>
    <arm_group_label>oxytocin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>balloon catheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dufour 1859H18</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>oxytocin</intervention_name>
    <arm_group_label>oxytocin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>balloon catheter</intervention_name>
    <arm_group_label>balloon catheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Pregnancy over 37 weeks

          -  Singleton pregnancy

          -  Vertex presentation

          -  Previous caesarean section with unique Transversal segmentary incision

          -  Medical indication of induction of labor

          -  Unfavorable cervix with Bishop score &lt; 4

          -  No Premature Rupture Of Membranes

          -  Informed consent

        Exclusion Criteria:

          -  Before 18 years old

          -  Placenta Praevia

          -  Premature Rupture Of Membranes

          -  Uterine scar other than transversal segmentary incision

          -  Cervical infection (except Streptoccoccus Agalactiae carrier) or choriamnionitis

          -  Multiple pregnancy

          -  Fetal malpresentation

          -  Cesarean indication

          -  Latex allergy

          -  No informed consent
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Fabrice Pierre</last_name>
    <email>f.pierre@chu-poitiers.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service Gynécologie Obstétrique</name>
      <address>
        <city>Angouleme</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MELIE SARREAU</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Gynécologie Obstétrique</name>
      <address>
        <city>Bressuire</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PASCAL VILLEMONTEIX</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Gynécologie Obstétrique</name>
      <address>
        <city>Chatellerault</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>ALAIN GODARD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Gynécologie Obstétrique</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>OLIVIER MOREL</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Gynécologie Obstétrique et médecine de la reproduction</name>
      <address>
        <city>Poitiers</city>
        <zip>86021</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>FABRICE PIERRE</last_name>
      <phone>(+33) 5 49 44 39 45</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Gynécologie Obstétrique</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>PATRICE POULAIN</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Service Gynécologie Obstétrique</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>VAYSSIERE</last_name>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 19, 2012</lastchanged_date>
  <firstreceived_date>August 23, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cicatrix</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Oxytocin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
